Fortress Biotech-Founded Journey Medical Releases Efficacy Data for Rosacea Drug Emrosi
October 25, 2025
October 25, 2025
WASHINGTON, Oct. 25 -- Journey Medical Corp., Scottsdale, Arizona, a commercial-stage pharmaceutical company founded by Fortress Biotech Inc., announced efficacy results from a combined analysis of its Phase 3 clinical trials for Emrosi (DFD-29), a treatment designed for the inflammatory lesions associated with rosacea in adults.
The data, pooled from the MVOR-1 and MVOR-2 multicenter studies, was presented at the 2025 Fall Clinical Dermatology Conference. The two parallel-group, r . . .
The data, pooled from the MVOR-1 and MVOR-2 multicenter studies, was presented at the 2025 Fall Clinical Dermatology Conference. The two parallel-group, r . . .